



FOR IMMEDIATE RELEASE

Public Relations Contact:

Nicole Elovitz
HemCon Medical Technologies, Inc.
503-245-0459
nicolee@hemcon.com

More Flexible Hemostatic Dressing Now Available for Clinical Settings New HemCon[®] Patch Provides Improved Comfort and Care

PORTLAND, Ore. – Feb. 24, 2009 – [HemCon Medical Technologies, Inc.](#) today announced that its flexible-by-design [HemCon[®] Patch](#) is now available for use for external, temporary control of bleeding during interventional and diagnostic cardiac catheterization, interventional radiology, electrophysiology and dialysis access procedures.

Offering diagnostic and interventional patients a quick, safe and comfortable post-procedural experience, the HemCon Patch delivers a flexible hemostatic solution where rapid arterial hemostasis is critically important to ensure quality care and safety. It reliably and quickly stops bleeding, minimizes risk of artery damage and frees up medical personnel.

“The HemCon Patch is a safe, effective option for achieving hemostasis, and its antibacterial barrier adds a layer of protection against dangerous patient infections,” said Dr. Ziyad Hijazi, director of the Rush Center for Congenital and Structural Heart Disease at Rush University Medical Centers. “Using the HemCon Patch, we have been able to decrease our hold times and bed rest requirements in addition to providing improved patient comfort. Its proven efficacy makes it the right non-invasive hemostatic choice for medical professionals who want to improve the standard of patient care and safety while also improving their bottom line.”

As one of the only hemostatic products to obtain an FDA [antibacterial barrier claim](#), the HemCon Patch provides a barrier against a wide spectrum of micro-organisms, including methicillin-resistant *Staphylococcus aureus* (MRSA), *Enterococcus faecalis* (VRE) and *Acinetobacter baumannii*. This unique barrier may help to reduce the risk of hospital-acquired infections for both patients and providers. The HemCon Patch is also ideal for patients that take anticoagulant medications or suffer from clotting or bleeding disorders.

About HemCon Medical Technologies Inc.

HemCon Medical Technologies, Inc., is a leading global developer of advanced medical products designed to improve the standard of patient care. The company is responsible for developing the chitosan-based HemCon dressing used by thousands of military and civilian first responders and is changing wound care best practices in hospital, dental and clinical settings. In addition, HemCon is leading the charge to develop and license unique, life-saving medical advances, including Lyophilized Human Plasma and Nanospider™ technologies. HemCon is headquartered in Portland, Ore., with additional commercial operations in Ireland; England; Germany and the Czech Republic. For more information, please visit www.hemcon.com.

#